TuHURA Biosciences wins US patent covering delta opioid receptor antagonist cancer therapies
HURA•TuHURA Biosciences received U.S. Patent No. 12,734,168 for delta opioid receptor antagonist therapies in cancers linked to DOR-expressing MDSCs, with a stated term through 2043 before any potential extension.
1. Patent coverage
The patent, issued Sept. 15, 2026, covers combination approaches aimed at reducing immunosuppressive myelopoiesis to improve responses to immunotherapy. It also describes use beyond antibody-drug conjugates, including adoptive cell therapies such as CAR-T, Tregs and TILs.
